Intelligence Report · ~15 min read
Orthopedics · Spine Surgery Therapeutic Area Assessment
14 signals · 3 insights · 38 regulatory precedents
Type
Therapeutic Area AssessmentGenerated
Jul 24, 2026
Confidence
Moderate Confidence · 62%
Evidence
55 items
Sources
2
Executive Summary
Synthesized assessment from linked signals, findings, and evidence relationships.
Therapeutic area assessment for Orthopedics · Spine Surgery integrates 14 signals, 3 executive insights, and 38 regulatory precedents from the Humanexa intelligence graph. 0 portfolio assets maintain indication overlap in this area. Regulatory and competitive dynamics require cross-functional monitoring across linked entities.
Key Developments
Material intelligence events ranked by strategic relevance.
- signalJul 2, 2026
Hologic Recalls BioZorb Markers Due to Patient Complications Risk
Hologic has recalled its BioZorb 3D bioabsorbable markers following reports of patient complications.
View detail - signalJul 23, 2026
PVP with Pedicle Screw Fixation Shows Superior Outcomes in Elderly Osteoporotic Patients
The study found that combining percutaneous vertebroplasty with minimally invasive pedicle screw fixation significantly improved pain relief and functional recovery in elderly patients with osteoporotic vertebral compression fractures compared to PVP alone.
View detail - signalJul 20, 2026
Study on PVI Predictors in Laparoscopic Hysterectomy to Enhance Fluid Management
The study investigates predictors of Pleth Variability Index changes during laparoscopic hysterectomy, focusing on intraoperative positional shifts.
View detail - signalJul 20, 2026
Stryker's MILD Procedure Study to Assess Medicare Beneficiary Outcomes
A prospective study will evaluate the outcomes of the MILD procedure compared to a control group over 24 months.
View detail - regulatoryJul 23, 2026
FDA Rare Disease Innovation Hub
FDA created the Rare Disease Innovation Hub (the Hub) to serve as a point of collaboration and connectivity between CBER and CDER with the goal of ultimately improving outcomes for patients.
View detail - regulatoryJul 23, 2026
Domperidone: new contraindication in patients with phaeochromocytoma due to the risk of severe hypertension
The product information has been updated for all domperidone products, to include a contraindication for patients with confirmed or suspected phaeochromocytoma (a rare tumour of the adrenal gland), due to the risk of episodes of severe hypertension.
View detail - regulatoryJul 23, 2026
Opportunities for patients and the public to be involved in the work of the MHRA
How we engage and involve patients and the public in our regulatory decision-making.
View detail - regulatoryJul 20, 2026
Drug Trials Snapshots: PALSONIFY
PALSONIFY is a somatostatin receptor analog for the treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option.
View detail - insightJul 2, 2026
Hologic's BioZorb Recall Signals Regulatory and Market Challenges Ahead
The recall of Hologic's BioZorb markers due to patient complications poses significant risks to patient safety and regulatory compliance. This incident could lead to increased scrutiny from regulatory bodies and impact Hologic's market position and reputation in the surgical device sector. Regulatory context from FDA (Implantable Marker Recall: Hologic Removes BioZorb 3D Bioabsorbable Markers due to Risk for Patient Complications) supports the near-term read. Assessment grounded in 21 ranked evidence items (3 high-relevance).
View detail - insightJun 24, 2026
Impact of Bowel Preparation Trial on Infection Prevention Guidelines and Market Dynamics
This trial addresses a critical gap in surgical practices, potentially leading to significant changes in pre-surgical protocols for bowel preparation. The outcome could enhance patient comfort and reduce healthcare costs, making it a pivotal study for clinical strategy teams. Assessment grounded in 19 ranked evidence items (12 high-relevance).
View detail - insightJun 19, 2026
Tego Science's TPX-115 Trial: A Potential Game Changer in Orthopedic Regenerative Medicine
The initiation of the TPX-115 trial by Tego Science is significant as it could introduce a new treatment option for Partial-Thickness Rotator Cuff Tear, impacting the competitive landscape in orthopedic regenerative medicine. Success in this trial may enhance Tego Science's market position and influence treatment paradigms in this therapeutic area. Regulatory context from MHRA (MHRA scientific leader recognised in 2026 King’s Birthday Honours) supports the near-term read. Assessment grounded in 18 ranked evidence items (7 high-relevance).
View detail
Strategic Implications
Portfolio and competitive decisions informed by this intelligence profile.
Executive insights surface 3 risk-calibrated assessments for portfolio review. 38 Regunera precedents provide regulatory context for pathway and timing decisions. Monitor 0 companies with active signal exposure for competitive and portfolio shifts.
Supporting Evidence
Evidence-backed items with source attribution and confidence disclosure.
FDA Rare Disease Innovation Hub
83%FDA created the Rare Disease Innovation Hub (the Hub) to serve as a point of collaboration and connectivity between CBER and CDER with the goal of ultimately improving outcomes for patients.
Source: FDA
View evidenceDomperidone: new contraindication in patients with phaeochromocytoma due to the risk of severe hypertension
83%The product information has been updated for all domperidone products, to include a contraindication for patients with confirmed or suspected phaeochromocytoma (a rare tumour of the adrenal gland), due to the risk of episodes of severe hypertension.
Source: MHRA
View evidenceOpportunities for patients and the public to be involved in the work of the MHRA
83%How we engage and involve patients and the public in our regulatory decision-making.
Source: MHRA
View evidenceDrug Trials Snapshots: PALSONIFY
72%PALSONIFY is a somatostatin receptor analog for the treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option.
Source: FDA
View evidenceQualified Clinical Outcome Assessments (COA)
72%The table below lists qualified Clinical Outcome Assessments (COA).
Source: FDA
View evidencePhase 1 IND Procedures and Policies
72%Why this matters: sets a safety guidance precedent in the same sub-indication (ild) as Stryker.
Source: FDA
View evidenceHologic's BioZorb Recall Signals Regulatory and Market Challenges Ahead
52%The recall of Hologic's BioZorb markers due to patient complications poses significant risks to patient safety and regulatory compliance. This incident could lead to increased scrutiny from regulatory bodies and impact Hologic's market position and reputation in the surgical device sector. Regulatory context from FDA (Implantable Marker Recall: Hologic Removes BioZorb 3D Bioabsorbable Markers due to Risk for Patient Complications) supports the near-term read. Assessment grounded in 21 ranked evidence items (3 high-relevance).
Source: Humanexa Insight
View evidenceImpact of Bowel Preparation Trial on Infection Prevention Guidelines and Market Dynamics
73%This trial addresses a critical gap in surgical practices, potentially leading to significant changes in pre-surgical protocols for bowel preparation. The outcome could enhance patient comfort and reduce healthcare costs, making it a pivotal study for clinical strategy teams. Assessment grounded in 19 ranked evidence items (12 high-relevance).
Source: Humanexa Insight
View evidenceTego Science's TPX-115 Trial: A Potential Game Changer in Orthopedic Regenerative Medicine
61%The initiation of the TPX-115 trial by Tego Science is significant as it could introduce a new treatment option for Partial-Thickness Rotator Cuff Tear, impacting the competitive landscape in orthopedic regenerative medicine. Success in this trial may enhance Tego Science's market position and influence treatment paradigms in this therapeutic area. Regulatory context from MHRA (MHRA scientific leader recognised in 2026 King’s Birthday Honours) supports the near-term read. Assessment grounded in 18 ranked evidence items (7 high-relevance).
Source: Humanexa Insight
View evidence
Related Intelligence
Deep links to signals, insights, companies, and assets in the Humanexa graph.
Signals
- Hologic Recalls BioZorb Markers Due to Patient Complications Risk
Safety Signal
- PVP with Pedicle Screw Fixation Shows Superior Outcomes in Elderly Osteoporotic Patients
Trial Update
- Study on PVI Predictors in Laparoscopic Hysterectomy to Enhance Fluid Management
Trial Update
- Stryker's MILD Procedure Study to Assess Medicare Beneficiary Outcomes
Trial Update
- Study on Minoxidil's Impact on Flap Viability in Breast Reconstruction
Trial Update
- Study Compares Biceps Tenodesis Techniques in Patients Without Rotator Cuff Tears
Trial Update
- Stryker initiates clinical evaluation of Femoral Nail GT for femur fractures
Trial Update
- Study on Intraoperative Chest Tube Removal in Thoracoscopic Wedge Resection
Trial Update
Insights
- Hologic's BioZorb Recall Signals Regulatory and Market Challenges Ahead
Surgery · Medical Devices
- Impact of Bowel Preparation Trial on Infection Prevention Guidelines and Market Dynamics
Surgery · Infection Prevention
- Tego Science's TPX-115 Trial: A Potential Game Changer in Orthopedic Regenerative Medicine
Orthopedics · Regenerative Medicine